DARE Dare Bioscience, Inc. Stock Quote

DARE [NASD]

Index	-	P/E	-	EPS (ttm)	-0.81	Insider Own	5.57%	Shs Outstand	50.44M	Perf Week	-10.56%
Market Cap	102.27M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	0.00%	Shs Float	47.69M	Perf Month	-16.76%
Income	-32.50M	PEG	-	EPS next Q	-0.13	Inst Own	4.90%	Short Float	3.48%	Perf Quarter	1.41%
Sales	-	P/S	-	EPS this Y	5.70%	Inst Trans	0.67%	Short Ratio	0.52	Perf Half Y	-6.49%
Book/sh	0.15	P/B	9.60	EPS next Y	-12.70%	ROA	-320.70%	Target Price	5.40	Perf Year	41.18%
Cash/sh	0.13	P/C	11.24	EPS next 5Y	-	ROE	-	52W Range	0.94 - 3.85	Perf YTD	7.46%
Dividend	-	P/FCF	-	EPS past 5Y	43.30%	ROI	-	52W High	-62.60%	Beta	1.55
Dividend %	-	Quick Ratio	2.30	Sales past 5Y	-	Gross Margin	-	52W Low	52.43%	ATR	0.08
Employees	23	Current Ratio	2.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	32.65	Volatility	6.08% 5.09%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	31.90%	Profit Margin	-	Rel Volume	0.85	Prev Close	1.47
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 12 AMC	Payout	-	Avg Volume	3.22M	Price	1.44
Recom	2.00	SMA20	-9.89%	SMA50	-12.44%	SMA200	-14.95%	Volume	2,733,680	Change	-2.04%

Oct-06-21 08:51AM	Daré Bioscience to Participate in Panel Discussion at DTC Perspectives Xpectives.Health Summit, October 12-14, 2021 GlobeNewswire
Sep-27-21 08:00AM	Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1 GlobeNewswire
Sep-24-21 11:43AM	Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy Zacks
Sep-23-21 08:00AM	Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy GlobeNewswire
Sep-22-21 08:00AM	Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-08-21 08:00AM	Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-07-21 08:00AM	Daré Bioscience to Participate in Panel Discussion at Womens Health Innovation Summit GlobeNewswire
Sep-01-21 08:00AM	Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause GlobeNewswire
Aug-12-21 08:00AM	Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update GlobeNewswire
Aug-09-21 08:00AM	Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis GlobeNewswire
06:20AM	Dare Bioscience Climbs on FDA Priority Review of Vaginosis Drug TheStreet.com
Aug-05-21 08:00AM	Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021 GlobeNewswire
Jul-26-21 08:00AM	Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021 GlobeNewswire
Jul-12-21 05:45AM	Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive GlobeNewswire -7.53%
Jul-07-21 08:20AM	Dare Bioscience stock rockets after new $49 million grant from Bill & Melinda Gates Foundation MarketWatch +23.68%
06:05AM	Dare Bioscience Jumps on Gates Foundation Grant Up to $49M TheStreet.com
Jun-28-21 08:00AM	Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1 GlobeNewswire
Jun-15-21 12:53PM	Is Dare Bioscience, Inc. (DARE) A Good Stock To Buy? Insider Monkey
Jun-04-21 08:00AM	Daré Bioscience to Present at 2021 BIO Digital GlobeNewswire
May-13-21 02:30PM	Dare Bioscience Inc to Host Earnings Call ACCESSWIRE
08:00AM	Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update GlobeNewswire
May-06-21 08:00AM	Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021 GlobeNewswire
Apr-27-21 08:00AM	Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists GlobeNewswire
Apr-26-21 08:00AM	Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists GlobeNewswire
Apr-19-21 08:00AM	Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors GlobeNewswire -5.71%
Mar-30-21 02:30PM	Dare Bioscience Inc to Host Earnings Call ACCESSWIRE
08:00AM	Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update GlobeNewswire
Mar-24-21 08:00AM	Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder GlobeNewswire
Mar-23-21 08:00AM	Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021 GlobeNewswire
Mar-22-21 08:00AM	Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Symptoms and Genitourinary Syndrome Associated with Menopause GlobeNewswire
Mar-10-21 08:00AM	Daré Bioscience to Participate in Upcoming Virtual Conferences GlobeNewswire
Mar-08-21 08:00AM	Daré Bioscience to Participate at the 33rd Annual Roth Conference GlobeNewswire
Mar-02-21 08:00AM	Daré Bioscience to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -5.03%
Feb-25-21 08:00AM	Daré Bioscience to Participate in Maxim Groups Late Stage Innovations in Womens Health Virtual Event GlobeNewswire -5.39%
Feb-16-21 08:00AM	Daré Bioscience to Participate at the Womens Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021 GlobeNewswire
Feb-09-21 08:00AM	Daré Bioscience to Present at the 2021 BIO CEO & Investor Digital Conference GlobeNewswire
Jan-05-21 08:00AM	Daré Bioscience to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference GlobeNewswire +6.11%
Dec-22-20 01:23AM	Is Now An Opportune Moment To Examine Daré Bioscience, Inc. (NASDAQ:DARE)? Simply Wall St. -5.76%
Dec-07-20 08:00AM	Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis GlobeNewswire -11.33%
Nov-12-20 02:30PM	Dare Bioscience Inc to Host Earnings Call ACCESSWIRE
08:00AM	Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update GlobeNewswire
Nov-05-20 08:00AM	Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020 GlobeNewswire
Oct-07-20 08:00AM	Daré Bioscience to Present at the 2020 BIO Investor Forum Digital GlobeNewswire +6.73%
Sep-21-20 08:00AM	Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1) GlobeNewswire
Sep-08-20 08:00AM	Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences GlobeNewswire
Sep-01-20 08:04AM	Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Darés Novel Pipeline of Womens Health Programs GlobeNewswire
Aug-20-20 08:00AM	Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis GlobeNewswire
Aug-19-20 08:00AM	Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1 Phase 1 Human Clinical Study for the Prevention of Preterm Birth GlobeNewswire
Aug-12-20 08:00AM	Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update GlobeNewswire
Aug-06-20 08:00AM	Daré Bioscience CEO to Participate in Maxim Groups Leading Innovators in Womens Health Virtual Conference GlobeNewswire
Aug-05-20 08:00AM	Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020 GlobeNewswire
Jul-27-20 08:00AM	Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms GlobeNewswire
Jul-13-20 07:02PM	3 Strong Buy Penny Stocks That Could Deliver Massive Returns TipRanks
Jun-17-20 08:00AM	Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis GlobeNewswire
Jun-15-20 08:00AM	Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive GlobeNewswire
Jun-04-20 08:00AM	Daré Bioscience Announces Participation in BIO Digital 2020 GlobeNewswire
May-17-20 03:02PM	Edited Transcript of DARE earnings conference call or presentation 14-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-14-20 08:00AM	Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update GlobeNewswire
May-11-20 08:00AM	Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Darés Novel Pipeline of Womens Health Programs GlobeNewswire
May-07-20 08:00AM	Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020 GlobeNewswire
Apr-28-20 08:00AM	Daré Bioscience CEO to Participate in Maxim Groups Infectious Disease Virtual Conference GlobeNewswire
Apr-23-20 08:00AM	Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC GlobeNewswire
Apr-08-20 04:24PM	Edited Transcript of DARE earnings conference call or presentation 30-Mar-20 8:30pm GMT Thomson Reuters StreetEvents
Apr-01-20 08:00AM	Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® GlobeNewswire
Mar-30-20 02:30PM	Dare Bioscience Inc to Host Earnings Call ACCESSWIRE
08:00AM	Daré Bioscience Reports 2019 Financial Results and Provides a Company Update GlobeNewswire
Mar-29-20 09:45AM	How Much Are Daré Bioscience, Inc. (NASDAQ:DARE) Insiders Spending On Buying Shares? Simply Wall St.
Mar-24-20 08:00AM	Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020 GlobeNewswire
Mar-10-20 08:00AM	Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis GlobeNewswire +5.88%
Mar-09-20 08:00AM	Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder GlobeNewswire
Feb-27-20 08:00AM	Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference GlobeNewswire
Feb-12-20 04:05PM	Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO GlobeNewswire
Feb-06-20 08:00AM	Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates GlobeNewswire +9.17%
Feb-05-20 08:00AM	Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire
Jan-30-20 08:00AM	Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule GlobeNewswire
Jan-22-20 06:55AM	Should You Be Concerned About Daré Bioscience, Inc.'s (NASDAQ:DARE) Historical Volatility? Simply Wall St.
Jan-17-20 12:19PM	Analysts: 3 Healthcare Stocks That Could Gain 35% Or More TipRanks
Jan-15-20 08:00AM	Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update GlobeNewswire +13.39%
Jan-13-20 07:00AM	Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive Business Wire +96.92%
Dec-18-19 08:00AM	Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study GlobeNewswire
Dec-11-19 08:00AM	Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire
Dec-10-19 08:00AM	Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems GlobeNewswire
Dec-09-19 07:15AM	DARE: Our Take On Ovaprene PCT Data, BV-1 Pivotal Study Design and Microchips Acquisition Zacks Small Cap Research
Dec-04-19 03:43PM	Edited Transcript of DARE earnings conference call or presentation 14-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-21-19 08:00AM	Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform GlobeNewswire
Nov-14-19 08:07AM	The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Benzinga
08:00AM	Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
Nov-12-19 08:00AM	Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate GlobeNewswire -7.57%
Nov-11-19 08:00AM	Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform GlobeNewswire +8.06%
Nov-07-19 08:30AM	Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast GlobeNewswire
Oct-31-19 08:00AM	Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360 GlobeNewswire
Oct-28-19 08:00AM	Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference GlobeNewswire
Oct-24-19 08:00AM	Companies Like Daré Bioscience (NASDAQ:DARE) Can Be Considered Quite Risky Simply Wall St.
Oct-14-19 08:00AM	Daré Bioscience to Participate in Two Upcoming Investor Conferences GlobeNewswire +14.23%
Oct-10-19 08:00AM	Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo GlobeNewswire
Oct-07-19 08:00AM	Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference GlobeNewswire
Sep-13-19 02:04PM	Edited Transcript of DARE earnings conference call or presentation 14-Aug-19 8:30pm GMT Thomson Reuters StreetEvents +8.86%
Sep-11-19 08:00AM	Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics GlobeNewswire
Sep-09-19 12:13PM	Could The Daré Bioscience, Inc. (NASDAQ:DARE) Ownership Structure Tell Us Something Useful? Simply Wall St.
08:00AM	Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder GlobeNewswire

Dare Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience